Harvard Bioscience Projects Q4 Adjusted EBITDA of $3.8 Million to $4.2 Million

Harvard Bioscience, Inc. forecast fourth-quarter 2026 adjusted EBITDA of $3.8 million to $4.2 million, above its third-quarter result of $1.8 million, while projecting revenue of $23.7 million to $25.5 million.

Adjusted EBITDA was $1.8 million in the third quarter of 2026, compared with $2 million in the same quarter a year earlier. The company describes the measure as non-GAAP.

Harvard Bioscience did not provide a GAAP reconciliation for its forward-looking adjusted EBITDA range because potential excluded charges or gains are difficult to predict. Adjusted EBITDA measures earnings before interest, taxes, depreciation and amortization, modified by specified adjustments.

Project Viking, a manufacturing consolidation, is expected to be completed by the end of the first quarter of 2027. It targets $3 million in savings during 2027 and $4 million in annual savings from 2028 onward.